Crucial Data Solutions’ eClinical Platforms Reach 10,000 Users


The first quarter of 2019 has brought about a meaningful milestone for Crucial Data Solutions. Users of Clinical Studio, our web-based eClinical platform, and TrialKit, our eClinical native mobile app, have surpassed the 10,000 mark.


Since the day Clinical Studio was created, we have been dedicated to lowering the cost of clinical research by offering powerful technology tools at a transparent, affordable cost. Nothing inspires us more than seeing research professionals around the world conduct compliant trials that will better medical treatments in a wide variety of areas. Even better, they’re able to achieve significant cost savings while utilizing better tools needed to more efficiently collect and analyze clinical data.


The geographic plot (above) shows various research sites across the globe. Clinical Studio and TrialKit are currently used by clinical research associates (CRAs), clinical research coordinators (CRCs), data managers, biostatisticians, and other clinical data specialists in the following countries:


United States of America


Canada


Mexico


Dominican Republic


Panama


Colombia


Brazil


Paraguay


United Kingdom


Ireland


Portugal


Spain


France


Italy


Switzerland


Austria


Germany


Belgium


Netherlands


Denmark


Norway


Sweden


Hungary


Czechia


Poland


Russia


Iran


Jordan


South Africa


United Arab Emirates


India


China


South Korea


Taiwan


Malaysia


Australia


Clinical Studio and TrialKit users aren’t just limited to research professionals. Patients are participating in clinical trials and submitting data on the platform by the thousands, too. Many of them are even utilizing wearables and features such as geo-positioning, accelerometer, and gyroscope to generate real-world data (RWD).


We look forward to the rest of 2019 and the years ahead as we continue to forge an innovational path in the clinical trials industry, helping research teams and patients everywhere.

Login or Signup to post a comment